The thesis

Prenetics Global Limited provides diagnostic and genetic testing services with 107.7% revenue growth. The company's net margin is -6245.0%, indicating significant losses. With a conviction score of 41/100, the setup is interesting due to the contrast between strong revenue growth and poor profitability. Analyst consensus is BUY, despite a DCF intrinsic value of $-1121.

Why now

The current macro context, including China's chip tool push and the US-China squeeze, adds uncertainty to the company's prospects. With revenue growth slowing potentially, the next quarter's earnings report will be crucial in assessing the company's ability to turn profitable.

What to watch

The next earnings report will be critical in assessing the company's ability to improve its net margin and reduce losses. Investors should watch for revenue growth, gross margin, and net margin improvements over the next 1-3 quarters to confirm or deny the thesis.

Key risks

Valuation risk is a major concern due to the company's significant losses and negative intrinsic value. Execution risk is also high, as Prenetics needs to improve its profitability to justify the analyst consensus BUY rating. Macro risk, including geopolitical tensions, may impact the company's supply chain and growth prospects.